

Publikationen aus der Klinik für Psychiatrie und Psychotherapie 2018

Anzahl Publikationen: 205
Anzahl IF-Arbeiten: 162
IF-Summe: 896.585

1. **Alexopoulos P, Gleixner LS, Werle L, Buhl F, Thierjung N, Giourou E, Kagerbauer SM, Gourzis P, Kübler H, Grimmer T, Yakushev I, Martin J, Kurz A, Perneczky R**
Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer's disease.
Eur Arch Psychiatry Clin Neurosci 2018; 268: 519-524. IF 3.192
2. **Alexopoulos P, Roesler J, Werle L, Thierjung N, Lentzari I, Ortner M, Grimmer T, Laskaris N, Politis A, Gourzis P, Kurz A, Perneczky R; Alzheimer's Disease Neuroimaging Initiative**
Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease.
J Neural Transm 2018; 125: 193-201 IF 2.903
3. **Alexopoulos P, Thierjung N, Grimmer T, Ortner M, Economou P, Assimakopoulos K, Gourzis P, Politis A, Perneczky R; The Alzheimer's Disease Neuroimaging Initiative**
Cerebrospinal Fluid BACE1 Activity and sA β PP β as Biomarker Candidates of Alzheimer's Disease.
Dement Geriatr Cogn Disord 2018; 45: 152-161. IF 2.260
4. **Arzberger T, Schludi MH, Lehmer C, Schmid B, Edbauer D**
RNA versus protein toxicity in C9orf72 ALS/FTLD.
Acta Neuropathol 2018; 135: 475-479. IF 18.174
5. **Asselmann E, Hilbert K, Hoyer J, Wittchen HU, Lieb R, Bühringer G, Beesdo-Baum K**
Self-reported volitional control in adolescents and young adults from a community cohort: Associations with current, past and future mental disorders.
Psychiatry Res 2018; 260: 292-299. IF 2.208
6. **Asselmann E, Venz J, Wittchen HU, Martini J**
Maternal anxiety and depressive disorders prior to, during and after pregnancy and infant interaction behaviors during the Face-to-Face Still Face Paradigm at 4 months postpartum: A prospective-longitudinal study.
Early Hum Dev 2018; 122: 45-53. IF 1.853
7. **Asselmann E, Wittchen HU, Lieb R, Beesdo-Baum K**
Sociodemographic, clinical, and functional long-term outcomes in adolescents and young adults with mental disorders.
Acta Psychiatr Scand 2018; 137: 6-17. IF 4.694
8. **Asselmann E, Wittchen HU, Lieb R, Perkonigg A, Beesdo-Baum K**
Incident mental disorders in the aftermath of traumatic events: A prospective-longitudinal community study.
J Affect Disord 2018; 227: 82-89 IF 4.084

9. **Aydogan G, Jobst A, Loy F, Dehning S, Zill P, Müller N, Kocher M**
The effect of oxytocin on group formation and strategic thinking in men.
Horm Behav. 2018; 100: 100-106. IF 3.949
10. **Baghai TC, Varallo-Bedarida G, Born C, Häfner S, Schüle C, Eser D, Zill P, Manook A, Weigl J, Jooyandeh S, Nothdurfter C, von Schacky C, Bondy B, Rupprecht R**
Classical Risk Factors and Inflammatory Biomarkers: One of the Missing Biological Links between Cardiovascular Disease and Major Depressive Disorder.
Int J Mol Sci 2018; 19; 1740. IF 4.183
11. **Bajbouj M, Aust S, Spies J, Herrera-Melendez AL, Mayer SV, Peters M, Plewnia C, Fallgatter AJ, Frase L, Normann C, Behler N, Wulf L, Brakemeier EL, Padberg F**
PsychotherapyPlus: augmentation of cognitive behavioral therapy (CBT) with prefrontal transcranial direct current stimulation (tDCS) in major depressive disorder-study design and methodology of a multicenter double-blind randomized placebo-controlled trial.
Eur Arch Psychiatry Clin Neurosci. 2018; 268: 797-808. IF 3.192
12. **Bartl H, Buschert V, Zwanzger P, Diemer J, Brunbauer A**
Evaluation einer neuropsychologischen Testbatterie an psychiatrischen und psychosomatischen Patienten
Fortschr Neurol Psychiatr 2018; 86: 348-355. IF 0.635
13. **Barton B, Schramm E, Voderholzer U**
Short and long-term efficacy of psychotherapy compared to pharmacological treatment for depression.
Zeitschrift für Psychiatrie, Psychologie und Psychotherapie (ZPPP) 2018; 66: 19-29. IF -
14. **Batra A, Jähne A, Rütger T**
Tabakabhängigkeit (ICD-10 F17.2).
In: Voderholzer U, Hohagen F (Hrsg.)
Therapie psychischer Erkrankungen. State of the Art.
Urban & Fischer, 2018, 81-92.
15. **Beesdo-Baum K, Knappe S, Einsle F, Knothe L, Wieder G, Venz J, Rummel-Kluge C, Heinz I, Koburger N, Schouler-Ocak M, Wilbertz T, Unger HP, Walter U, Hein J, Hegerl U, Lieb R, Pfennig A, Schmitt J, Hoyer J, Wittchen HU, Bergmann A**
Wie häufig werden Patienten mit depressiven Störungen in der hausärztlichen Praxis erkannt? Eine epidemiologische Querschnittsstudie.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018;61: 52-64. IF 0.945
16. **Behler N, Leitner B, Mezger E, Weidinger E, Musil R, Blum B, Kirsch B, Wulf L, Löhrs L, Winter C, Padberg F, Palm U**
Cathodal tDCS Over Motor Cortex Does Not Improve Tourette Syndrome: Lessons Learned From a Case Series.
Front Behav Neurosci. 2018; 12: 194. IF 2.622
17. **Berger M, Juster RP, Westphal S, Amminger GP, Bogerts B, Schiltz K, Bahn S, Steiner J, Sarnyai Z**
Allostatic load is associated with psychotic symptoms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis.
Psychoneuroendocrinology. 2018; 90: 35-42. IF 4.013
18. **Beyer L, Meyer-Wilmes J, Schönecker S, Schnabel J, Brendel E, Prix C, Nübling G, Unterrainer M, Albert NL, Pogarell O, Pernecky R, Catak C, Bürger K, Bartenstein P, Bötzel K, Levin J, Rominger A, Brendel M**

Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?
Front Neurol. 2018; 9: 483. IF 2.635

19. **Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium**
Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes.
Cell 2018; 173: 1705-1715. IF 36.216
20. **Bischoff S, Wieder G, Einsle F, Petzold MB, Janßen C, Mumm JLM, Wittchen HU, Fydrich T, Plag J, Ströhle A**
Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia.
J Psychiatr Res 2018; 101: 34-41. IF 3.917
21. **Brakemeier EL, Dobias J, Hertel J, Bohus M, Limberger MF, Schramm E, Radtke M, Frank P, Padberg F, Sabass L, Jobst A, Jacob GA, Struck N, Zimmermann J, Normann C**
Childhood Maltreatment in Women with Borderline Personality Disorder, Chronic Depression, and Episodic Depression, and in Healthy Controls.
Psychother Psychosom 2018; 87: 49-51. IF 13.744
22. **Breitschuh S, Schöne M, Tozzi L, Kaufmann J, Strumpf H, Fenker D, Frodl T, Bogerts B, Schiltz K**
Aggressiveness of martial artists correlates with reduced temporal pole grey matter concentration.
Psychiatry Res Neuroimaging. 2018; 281: 24-30. IF 2.270
23. **Brendel M, Sauerbeck J, Greven S, Kotz S, Scheiwein F, Blautzik J, Delker A, Pogarell O, Ishii K, Bartenstein P, Rominger A; Alzheimer's Disease Neuroimaging Initiative**
Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
J Alzheimers Dis 2018; 65: 793-806. IF 3.517
24. **Brinker TJ, Brieske CM, Esser S, Klode J, Mons U, Batra A, Rütger T, Seeger W, Enk AH, von Kalle C, Berking C, Heppt MV, Gatzka MV, Bernardes-Souza B, Schlenk RF, Schadendorf D**
A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic.
J Med Internet Res 2018; 20: e10976. IF 4.945
25. **Brunelin J, Mondino M, Bation R, Palm U, Saoud M, Poulet E**
Transcranial Direct Current Stimulation for Obsessive-Compulsive Disorder: A Systematic Review.
Brain Sci 2018; 8; E37 IF 2.786
26. **Brunnauer A**
Antidepressiva und Fahrtauglichkeit – ein Update klinischer Untersuchungen.
Internistische Praxis 2018; 59: 101-109. IF -
27. **Brunnauer A**
Der Bahnunfall bei Bad Aibling – Vergessen durch Ablenkung.

Zeitschrift für Verkehrssicherheit 2018; 64: 129-130. IF -

28. **Brunnauer A, Segmiller FM, Löschner S, Grun V, Padberg F, Palm U**
The Effects of Transcranial Direct Current Stimulation (tDCS) on Psychomotor and Visual Perception Functions Related to Driving Skills.
Front Behav Neurosci 2018; 12: 16. IF 2.622
29. **Brunoni AR, Padberg F, Vieira ELM, Teixeira AL, Carvalho AF, Lotufo PA, Gattaz WF, Benseñor IM**
Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression.
Prog Neuropsychopharmacol Biol Psychiatry 2018; 86: 211-217. IF 4.315
30. **Buchheim A, Labek K, Taubner S, Kessler H, Pokorny D, Kächele H, Cierpka M, Roth G, Pogarell O, Karch S**
Modulation of Gamma Band Activity and Late Positive Potential in Patients with Chronic Depression after Psychodynamic Psychotherapy.
Psychother Psychosom 2018; 87: 252-254. IF 13.744
31. **Canuto A, Weber K, Baertschi M, Andreas S, Volkert J, Dehoust MC, Sehner S, Suling A, Wegscheider K, Ausín B, Crawford MJ, Da Ronch C, Grassi L, HersHKovitz Y, Muñoz M, Quirk A, Rotenstein O, Santos-Olmo AB, Shalev A, Strehle J, Wittchen HU, Schulz H, Härter M**
Anxiety Disorders in Old Age: Psychiatric Comorbidities, Quality of Life, and Prevalence According to Age, Gender, and Country.
Am J Geriatr Psychiatry 2018 ; 26: 174-185 IF 3.488
32. **Chalah MA, Palm U, Lefaucheur JP, Créange A, Ayache SS**
Interhemispheric inhibition predicts anxiety levels in multiple sclerosis: A corticospinal excitability study.
Brain Res. 2018; 1699: 186-194. IF 2.929
33. **Chekroud AM, Foster D, Zheutlin AB, Gerhard DM, Roy B, Koutsouleris N, Chandra A, Esposti MD, Subramanyan G, Gueorguieva R, Paulus M, Krystal JH**
Predicting Barriers to Treatment for Depression in a U.S. National Sample: A Cross-Sectional, Proof-of-Concept Study.
Psychiatr Serv 2018; 69: 927-934. IF 2.253
34. **Chekroud AM, Koutsouleris N**
The perilous path from publication to practice.
Mol Psychiatry 2018 Jan; 23: 24-25. IF 11.973
35. **Cimpianu CL, Schiltz K**
Der aggressive Patient.
MMW Fortschr Med 2018; 160: 45-47. IF -
36. **Comes AL, Papiol S, Mueller T, Geyer PE, Mann M, Schulze TG**
Proteomics for blood biomarker exploration of severe mental illness: pitfalls of the past and potential for the future.
Transl Psychiatry 2018; 8: 160. IF 5.182
37. **Dauber H, Braun B, Pfeiffer-Gerschel T, Kraus L, Pogarell O**
Co-occurring Mental Disorders in Substance Abuse Treatment: the Current Health Care Situation in Germany.

Int J Ment Health Addict 2018; 16: 66-80. IF 1.420

38. **Dauber H, Pogarell O, Kraus L, Braun B**
Older adults in treatment for alcohol use disorders: service utilisation, patient characteristics and treatment outcomes.
Subst Abuse Treat Prev Policy 2018; 13: 40. IF 2.101
39. **Dewald-Kaufmann JF, Bruin EJ, Smits M, Zijlstra BJH, Oort FJ, Meijer AM**
Chronic sleep reduction in adolescents-clinical cut-off scores for the Chronic Sleep Reduction Questionnaire (CSRQ).
J Sleep Res 2018; 27: e12653. IF 3.432
40. **Diedrich A, Schlegl S, Greetfeld M, Fumi M, Voderholzer U**
Intensive inpatient treatment for bulimia nervosa: Statistical and clinical significance of symptom changes.
Psychother Res 2018; 28: 297-312. IF 2.788
41. **Dittmer N, Jacobi C, Voderholzer U**
Compulsive exercise in eating disorders: proposal for a definition and a clinical assessment.
J Eat Disord 2018; 6: 42. IF -
42. **Dittmer N, Voderholzer U, von der Mühlen M, Marwitz M, Fumi M, Mönch C, Alexandridis K, Cuntz U, Jacobi C, Schlegl S**
Specialized group intervention for compulsive exercise in inpatients with eating disorders: feasibility and preliminary outcomes.
J Eat Disord 2018; 6: 27. IF -
43. **Donse L, Padberg F, Sack AT, Rush AJ, Arns M**
Simultaneous rTMS and psychotherapy in major depressive disorder: Clinical outcomes and predictors from a large naturalistic study.
Brain Stimul 2018; 11: 337-345. IF 6.919
44. **Druschky K, Bleich S, Grohmann R, Burda K, Frieling H, Hillemacher T, Neyazi A, Stübner S, Toto S**
Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries.
Eur Psychiatry 2018; 54: 117-123. IF 3.941
45. **Druschky K, Bleich S, Grohmann R, Engel RR, Kleimann A, Stübner S, Greil W, Toto S**
Use and safety of antiepileptic drugs in psychiatric inpatients-data from the AMSP study.
Eur Arch Psychiatry Clin Neurosci 2018; 268: 191-208. IF 3.192
46. **Druschky K, Bleich S, Grohmann R, Engel RR, Neyazi A, Stübner S, Toto S**
Seizure rates under treatment with antipsychotic drugs - data from the AMSP project.
World J Biol Psychiatry 2018; 30: 1-29. IF 4.040
47. **Dwyer DB, Cabral C, Kambeitz-Ilankovic L, Sanfelici R, Kambeitz J, Calhoun V, Falkai P, Pantelis C, Meisenzahl E, Koutsouleris N**
Brain Subtyping Enhances The Neuroanatomical Discrimination of Schizophrenia.
Schizophr Bull 2018; 44: 1060-1069. IF 7.289
48. **Dwyer DB, Falkai P, Koutsouleris N**
Machine Learning Approaches for Clinical Psychology and Psychiatry.

Annu Rev Clin Psychol 2018; 14: 91-118. IF 14.098

49. **Edemann-Callesen H, Habelt B, Wieske F, Jackson M, Khadka N, Mattei D, Bernhardt N, Heinz A, Liebetanz D, Bikson M, Padberg F, Hadar R, Nitsche MA, Winter C**
Non-invasive modulation reduces repetitive behavior in a rat model through the sensorimotor cortico-striatal circuit.
Transl Psychiatr 2018; 8: 11. IF 5.182
50. **Esser P, Hartung TJ, Friedrich M, Johansen C, Wittchen HU, Faller H, Koch U, Härter M, Keller M, Schulz H, Wegscheider K, Weis J, Mehnert A**
The Generalized Anxiety Disorder Screener (GAD-7) and the anxiety module of the Hospital and Depression Scale (HADS-A) as screening tools for generalized anxiety disorder among cancer patients.
Psychooncology 2018; 27: 1509-1516. IF 3.430
51. **Falkai P**
Verhaltensauffälliger Patient: was tun?
MMW Fortschr Med 2018; 160: 44. IF -
52. **Falkai P**
Zukunftsweisende Forschungsansätze in der Psychiatrie.
Fortschr Neurol Psychiatr 2018; 86: 16-17. IF 0.635
53. **Falkai P, Gaebel W**
Beginn einer neuen Serie: Psychiatrische und neurologische Schwerpunktheft. Beginning of a new series: psychiatry and neurology based issues.
Fortschr Neurol Psychiatr 2018; 86: 147-148. IF 0.635
54. **Falkai P, Schmitt A, Koutsouleris N**
Impaired recovery in affective disorders and schizophrenia: sharing a common pathophysiology?
Eur Arch Psychiatry Clin Neurosci 2018; 268: 739-740. IF 3.192
55. **Foo JC, Streit F, Treutlein J, Ripke S, Witt SH, Strohmaier J, Degenhardt F, Forstner AJ, Hoffmann P, Soyka M, Dahmen N, Scherbaum N, Wodarz N, Heilmann-Heimbach S, Herms S, Cichon S, Preuss U, Gaebel W, Ridinger M, Hoffmann S, Schulze TG, Maier W, Zill P, Müller-Myhsok B, Ising M, Lucae S, Nöthen MM, Mann K, Kiefer F, Rietschel M, Frank J; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium**
Shared genetic etiology between alcohol dependence and major depressive disorder.
Psychiatr Genet 2018; 28: 66-70. IF 1.375
56. **Fortmann T, Pogarell O**
Alzheimerdiagnostik: Unterschiede in funktioneller und effektiver Hirnkonnektivität
Klin Neurophysiol 2018; 49: 70-71. IF
57. **Franke ML, Lersner UV, Essel OQ, Adorjan K, Schomerus G, Gómez-Carrillo A, Tam Ta TM, Böge K, Mobashery M, Dettling M, Diefenbacher A, Angermeyer MC, Hahn E**
The relationship between causal beliefs and desire for social distance towards people with schizophrenia and depression: Results from a survey of young Ghanaian adults.
Psychiatry Res 2018; 271: 220-225. IF 2.208
58. **Franke AG, Neumann, Soyka M**
Konsum von Crystal Meth. Medizinische und psychosoziale Determinanten in

Diagnostik und Therapie.
Info Neurologie Psychiatrie 2018; 20: 34-38. IF -

59. **Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, Dichgans M, Haass C, Suárez-Calvet M, Fagan AM, Paumier K, Benzinger T, Masters CL, Morris JC, Pernecky R, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Teipel S, Kilimann I, Ramirez A, Rossor M, Jucker M, Chhatwal J, Spottke A, Boecker H, Brosseron F, Falkai P, Fliessbach K, Heneka MT, Laske C, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Kofler B, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Weiner M, Lee JH, Salloway S, Danek A, Goate A, Schofield PR, Bateman RJ, Ewers M**
Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.
Brain 2018 ; 141: 1186-1200. IF 11.814
60. **Gaebel W, Riesbeck M, Zielasek J, Kerst A, Meisenzahl-Lechner E, Köllner V, Rose M, Hofmann T, Schäfer I, Lotzin A, Briken P, Klein V, Brunner F, Keeley JW, Rebello TJ, Andrews HF, Reed GM, Kostanjsek NFI, Hasan A, Russek P, Falkai P**
Internetbasierte Untersuchungen zur diagnostischen Klassifikation und Kodierung psychischer Störungen im Vergleich von ICD-11 und ICD-10.
Web-based field studies on diagnostic classification and code assignment of mental disorders: comparison of ICD-11 and ICD-10.
Fortschr Neurol Psychiatr 2018; 86: 163-171. IF 0.635
61. **Galderisi S, Falkai P**
Psychiatry and psychiatrists: Fourteen core statements.
Eur Psychiatry 2018; 52: 136-138. IF 3.941
62. **Galinski S, Wichert SP, Rossner MJ, Wehr MC**
Multiplexed profiling of GPCR activities by combining split TEV assays and EXT-based barcoded readouts.
Sci Rep 2018; 8: 8137. IF 4.011
63. **Gensichen J, Schultz S, Adrion C, Schmidt K, Schauer M, Lindemann D, Unruh N, Kosilek RP, Schneider A, Scherer M, Bergmann A, Heintze C, Joos S, Briegel J, Scherag A, König HH, Brettschneider C, Schulze TG, Mansmann U, Linde K, Lühmann D, Voigt K, Gehrke-Beck S, Koch R, Zwissler B, Schneider G, Gerlach H, Kluge S, Koch T, Walther A, Atmann O, Oltrogge J, Sauer M, Schnurr J, Elbert T; PICTURE Study Group**
Effect of a combined brief narrative exposure therapy with case management versus treatment as usual in primary care for patients with traumatic stress sequelae following intensive care medicine: study protocol for a multicenter randomized controlled trial (PICTURE).
Trials 2018; 19: 480. IF 1.975
64. **Gerwinn H, Weiß S, Tenbergen G, Amelung T, Födisch C, Pohl A, Massau C, Kneer J, Mohnke S, Kärigel C, Wittfoth M, Jung S, Drumkova K, Schiltz K, Walter M, Beier KM, Walter H, Ponseti J, Schiffer B, Kruger THC**
Clinical characteristics associated with paedophilia and child sex offending - Differentiating sexual preference from offence status.
Eur Psychiatry 2018; 51: 74-85. IF 3.941
65. **Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin JM, Yatham L, Mosolov S, Möller HJ, Kasper S; Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic**

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder.
World J Biol Psychiatry 2018; 19: 2-58. IF 4.040

66. **Günthner A, Weissinger V, Fleischmann H, Veltrup C, Jäpel B, Längle G, Amann K, Hoch E, Mann K**
[Health Care Organization - The New German S3-Guideline on Alcohol-Related Disorders and its Relevance for Health Care].
Rehabilitation 2018; 57: 314-320. IF 0.938
67. **Guggenmos M, Scheel M, Sekutowicz M, Garbusow M, Sebold M, Sommer C, Charlet K, Beck A, Wittchen HU, Zimmermann US, Smolka MN, Heinz A, Sterzer P, Schmack K**
Decoding diagnosis and lifetime consumption in alcohol dependence from grey-matter pattern information.
Acta Psychiatr Scand 2018; 137: 252-262. IF 4.694
68. **Häckert J, Falkai P, Perneczky R, Pogarell O**
Der sprachlose Patient.
MMW Fortschr Med 2018; 160: 53-56. IF -
69. **Handrack M, Voderholzer U, Schwartz C, Hasan A, Padberg F, Palm U**
Prefrontal direct current stimulation in hoarding disorder: A case report.
Brain Stimul 2018; 11: 634-635. IF 6.919
70. **Hansbauer M, Wobrock T, Kunze B, Langguth B, Landgrebe M, Eichhammer P, Frank E, Cordes J, Wölwer W, Winterer G, Gaebel W, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Malchow B, Strube W, Schneider-Axmann T, Falkai P, Hasan A**
Efficacy of high-frequency repetitive transcranial magnetic stimulation on PANSS factors in schizophrenia with predominant negative symptoms - Results from an exploratory re-analysis.
Psychiatry Res 2018; 263: 22-29. IF 2.208
71. **Harrison JE, Barry H, Baune BT, Best MW, Bowie CR, Cha DS, Culpepper L, Fossati P, Greer TL, Harmer C, Klag E, Lam RW, Lee Y, Mansur RB, Wittchen HU, McIntyre RS**
Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers.
Int J Methods Psychiatr Res 2018; 27: e1736. IF 2.276
72. **Hartmann H, Hornburg D, Czuppa M, Bader J, Michaelsen M, Farny D, Arzberger T, Mann M, Meissner F, Edbauer D**
Proteomics and *C9orf72* neuropathology identify ribosomes as poly-GR/PR interactors driving toxicity.
Life Sci Alliance 2018; 1: e201800070. IF -
73. **Henssler J, Schubert T, Soyka M**
Beruhigungsmittel: Sedativa und Hypnotika.
In: von Heyden M, Jungaberle H, Majic T (Hrsg.)
Handbuch Psychoaktive Substanzen. Springer, Berlin, 2018, S. 585-607.
74. **Herholt A, Brankatschk B, Kannaiyan N, Papiol S, Wichert SP, Wehr MC, Rossner MJ**
Pathway sensor-based functional genomics screening identifies modulators of neuronal

activity.

Sci Rep 2018; 8: 17597. IF 4.011

75. **Hessler JB, Diedrich A, Greetfeld M, Schlegl S, Schwartz C, Voderholzer U**
Weight Suppression But Not Symptom Improvement Predicts Weight Gain During Inpatient Treatment for Bulimia Nervosa.
Eur Eat Disord Rev 2018; 26: 146-149. IF 3.154
76. **Hofer PD, Wahl K, Meyer AH, Miché M, Beesdo-Baum K, Wong SF, Grisham JR, Wittchen HU, Lieb R**
Obsessive-compulsive disorder and the risk of subsequent mental disorders: A community study of adolescents and young adults.
Depress Anxiety 2018; 35: 339-345 IF 4.935
77. **Hofer PD, Wahl K, Meyer AH, Miche M, Beesdo-Baum K, Wittchen HU, Lieb R**
The role of behavioral inhibition, perceived parental rearing, and adverse life events in adolescents and young adults with incident obsessive-compulsive disorder
Journal Obsessive-Compulsive Relat Disord 2018; 19: 116-123. IF 1.391
78. **Hommers LG, Richter J, Yang Y, Raab A, Baumann C, Lang K, Schiele MA, Weber H, Wittmann A, Wolf C, Alpers GW, Arolt V, Domschke K, Fehm L, Fydrich T, Gerlach A, Gloster AT, Hamm AO, Helbig-Lang S, Kircher T, Lang T, Pané-Farré CA, Pauli P, Pfeleiderer B, Reif A, Romanos M, Straube B, Ströhle A, Wittchen HU, Frantz S, Ertl G, Lohse MJ, Lueken U, Deckert J**
A functional genetic variation of SLC6A2 repressor hsa-miR-579-3p upregulates sympathetic noradrenergic processes of fear and anxiety.
Transl Psychiatry 2018; 8: 226. IF 5.182
79. **International Consortium on Lithium Genetics (ConLi+Gen), Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Heilbronner U, Degenhardt F, Tekola-Ayele F, Hsu YH, Shekhtman T, Adli M, Akula N, Akiyama K, Ardaur R, Arias B, Aubry JM, Backlund L, Bhattacharjee AK, Bellivier F, Benabarre A, Bengesser S, Biernacka JM, Birner A, Brichant-Petitjean C, Cervantes P, Chen HC, Chillotti C, Cichon S, Cruceanu C, Czerski PM, Dalkner N, Dayer A, Del Zompo M, DePaulo JR, Étain B, Falkai P, Forstner AJ, Frisen L, Frye MA, Fullerton JM, Gard S, Garnham JS, Goes FS, Grigoriou-Serbanescu M, Grof P, Hashimoto R, Hauser J, Herms S, Hoffmann P, Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kuo PH, Kato T, Kelsoe J, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Tortorella A, Manchia M, Martinsson L, McCarthy MJ, McElroy S, Colom F, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Novák T, O'Donovan C, Ozaki N, Ösby U, Pfennig A, Potash JB, Reif A, Reininghaus E, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schweizer BW, Severino G, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Squassina A, Stamm T, Stopkova P, Maj M, Turecki G, Vieta E, Volkert J, Witt S, Wright A, Zandi PP, Mitchell PB, Bauer M, Alda M, Rietschel M, McMahon FJ, Schulze TG, Baune BT**
Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study.
JAMA Psychiatry 2018; 75: 65-74 IF 15.916
80. **International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OC GAS)**
Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis.

Mol Psychiatry 2018; 23: 1181-1188. IF 11.973

81. **Isaksson S, Salomäki S, Tuominen J, Arstila V, Falter-Wagner CM, Noreika V**
Is there a generalized timing impairment in Autism Spectrum Disorders across time scales and paradigms?
J Psychiatr Res 2018; 99: 111-121. IF 3.917
82. **Jobst A, Sabaß L, Hall D, Brücklmeier B, Buchheim A, Hall J, Sarubin N, Zill P, Falkai P, Brakemeier EL, Padberg F**
Oxytocin plasma levels predict the outcome of psychotherapy: A pilot study in chronic depression.
J Affect Disord 2018; 227: 206-213. IF 4.084
83. **Kambeitz J, Cabral C, Sacchet MD, Gotlib IH, Zahn R, Serpa MH, Walter M, Falkai P, Koutsouleris N**
Reply to: Sample Size, Model Robustness, and Classification Accuracy in Diagnostic Multivariate Neuroimaging Analyses.
Biol Psychiatry 2018; 84: e83-84. IF 11.501
84. **Kamp D, Engelke C, Wobrock T, Kunze B, Wölwer W, Winterer G, Schmidt-Kraepelin C, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Raees A, Honer WG, Malchow B, Schneider-Axmann T, Falkai P, Hasan A, Cordes J**
Letter to the Editor: Influence of rTMS on smoking in patients with schizophrenia.
Schizophr Res 2018; 192: 481-484. IF 4.569
85. **Kasper S, Müller WE, Volz HP, Möller HJ, Koch E, Diemel A**
Silexan in anxiety disorders: Clinical data and pharmacological background.
World J Biol Psychiatry 2018; 19: 412-420. IF 4.040
86. **Keller-Varady K, Varady PA, Röh A, Schmitt A, Falkai P, Hasan A, Malchow B**
A systematic review of trials investigating strength training in schizophrenia spectrum disorders.
Schizophr Res 2018; 192: 64-68. IF 4.569
87. **Kerkemeyer L, Wasem J, Neumann A, Brannath W, Mester B, Timm J, Wobrock T, Bartels C, Falkai P, Biermann J**
Effectiveness and cost-effectiveness of an integrated care program for schizophrenia: an analysis of routine data.
Eur Arch Psychiatry Clin Neurosci 2018; 268: 611-619. IF 3.192
88. **Kirchner SK, Roeh A, Nolden J, Hasan A**
Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review.
NPJ Schizophr 2017; 4: 20. IF –
89. **Kirsch V, Boegle R, Keeser D, Kierig E, Ertl-Wagner B, Brandt T, Dieterich M**
Handedness-dependent functional organizational patterns within the bilateral vestibular cortical network revealed by fMRI connectivity based parcellation.
Neuroimage 2018; 178: 224-237. IF 5.812
90. **Knappe S, Einsle F, Rummel-Kluge C, Heinz I, Wieder G, Venz J, Schouler-Ocak M, Wittchen H-U, Lieb R, Hoyer J, Schmitt J, Bergmann A, Beesdo-Baum K**
Niederschwellige leitlinienorientierte supportive Materialien (NILS) in der primärärztlichen Versorgung: Effekte auf die Orientierung an der S3/NV-Leitlinie

Unipolare Depression.

Z Psychosom Med Psychother 2018; 64: 298-311. IF -

91. **Koutsouleris N, Kambeitz-Ilankovic L, Ruhrmann S, Rosen M, Ruef A, Dwyer DB, Paolini M, Chisholm K, Kambeitz J, Haidl T, Schmidt A, Gillam J, Schultze-Lutter F, Falkai P, Reiser M, Riecher-Rössler A, Upthegrove R, Hietala J, Salokangas RKR, Pantelis C, Meisenzahl E, Wood SJ, Beque D, Brambilla P, Borgwardt S; PRONIA Consortium**
Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression: A Multimodal, Multisite Machine Learning Analysis.
JAMA Psychiatry 2018; 75: 1156-72. IF 15.916
92. **Koutsouleris N, Wobrock T, Guse B, Langguth B, Landgrebe M, Eichhammer P, Frank E, Cordes J, Wölwer W, Musso F, Winterer G, Gaebel W, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Dwyer D, Ghaseminejad F, Dechent P, Malchow B, Kreuzer PM, Poepl TB, Schneider-Axmann T, Falkai P, Hasan A**
Predicting Response to Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia Using Structural Magnetic Resonance Imaging: A Multisite Machine Learning Analysis.
Schizophr Bull 2018; 44: 1021-1034. IF 7.289
93. **Krammer S, Grosse Holtforth M, Burri A, Soyka M, Gamma A, Liebreiz M**
Interpersonal
Interpersonal sensitivity as a Mediator Between Cumulative Childhood Traumatic Events and Adult Sexual Disturbance.
J Sex Marital Ther 2018; 44: 213-220. IF 1.725
94. **Kranaster L, Hoyer C, Aksay SS, Bumb JM, Müller N, Zill P, Schwarz MJ, Sartorius A**
Antidepressant efficacy of electroconvulsive therapy is associated with a reduction of the innate cellular immune activity in the cerebrospinal fluid in patients with depression.
World J Biol Psychiatry 2018; 19: 379-389. IF 4.040
95. **Kranzler HR, Soyka M**
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
JAMA 2018; 320: 815-824. IF 51.273
96. **Krause D, Stapf TM, Kirnich VB, Hennings A, Riemer S, Chrobok A, Fries DR, Pedrosa Gil F, Rief W, Schwarz MJ, Schmidmaier R**
Stability of Cellular Immune Parameters over 12 Weeks in Patients with Major Depression or Somatoform Disorder and in Healthy Controls.
Neuroimmunomodulation 2018; 25: 7-17. IF 1.351
97. **Krause D, Warnecke M, Schuetz CG, Soyka M, Manz KM, Proebstl L, Kamp F, Chrobok AI, Pogarell O, Koller G**
The Impact of the Opioid Antagonist Naloxone on Experimentally Induced Craving in Nicotine-Dependent Individuals.
Eur Addict Res 2018; 24: 255-265. IF 1.957
98. **Kroll SL, Nikolic E, Bieri F, Soyka M, Baumgartner MR, Quednow BB**
Cognitive and socio-cognitive functioning of chronic non-medical prescription opioid users.

Psychopharmacology 2018; 235: 3451-3464. IF 3.424

99. **Krummenauer F, Bschor T, Valle E, Degner D, Grohmann, Toto S**
Respiratorische Insuffizienz mit Koma nach Lorazepam-Einnahme.
Psychopharmakotherapie 2018; 24: 283-285. IF -
100. **Kuitunen-Paul S, Pfab S, Garbusow M, Heinz A, Kuitunen PT, Manthey J, Nebe S, Smolka MN, Wittchen HU**
Identification of heavy drinking in the 10-item AUDIT: Results from a prospective study among 18-21years old non-dependent German males.
J Subst Abuse Treat 2018; 86: 94-101. IF 2.542
101. **Kurzeck AK, Kirsch B, Weidinger E, Padberg F, Palm U**
Transcranial Direct Current Stimulation (tDCS) for Depression during Pregnancy: Scientific Evidence and What Is Being Said in the Media-A Systematic Review.
Brain Sci 2018; 8: E155. IF 2.786
102. **Lambrechts A, Falter-Wagner CM, van Wassenhove V**
Diminished neural resources allocation to time processing in Autism Spectrum Disorders.
Neuroimage Clin 2018; 176: 124-136. IF 3.943
103. **Laux G, Brunnauer A**
Psychische Störungen.
In: Schubert W, Huetten M, Reimann C, Graw M, Schneider W, Stephan E (Hrsg.)
Begutachtungsleitlinien zur Kraftfahreignung. Kommentar.
Kirschbaum, Bonn, 2018; S. 231-243.
104. **Letmaier M, Grohmann R, Kren C, Toto S, Bleich S, Engel R, Gary T, Papageorgiou K, Konstantinidis A, Holl AK, Painold A, Kasper S**
Venous thromboembolism during treatment with antipsychotics: Results of a drug surveillance programme.
World J Biol Psychiatry 2018; 19: 175-186. IF 4.040
105. **Lett TA, Mohnke S, Amelung T, Brandl EJ, Schiltz K, Pohl A, Gerwinn H, Kärgel C, Massau C, Tenbergen G, Wittfoth M, Kneer J, Beier KM, Walter M, Ponseti J, Krüger THC, Schiffer B, Walter H**
Multimodal neuroimaging measures and intelligence influence pedophile child sexual offense behavior.
Eur Neuropsychopharmacol 2018; 28: 818-827. IF 4.468
106. **Leucht S, Fennema H, Engel RR, Kaspers-Janssen M, Szegedi A**
Translating the HAM-D into the MADRS and vice versa with equipercetile linking.
J Affect Disord 2018; 226: 326-331. IF 4.084
107. **Linhardt A, Haider R, Rampeltshammer V, Kröger C, Rütther T**
Rauchfreie Psychiatrie. Eine Bestandsaufnahme.
Fortschr Neurol Psychiatr 2018; 86: 213-218. IF 0.635
108. **Liu J, Heinsen H, Grinberg LT, Alho E, Amaro E Jr, Pasqualucci CA, Rüb U, den Dunnen W, Arzberger T, Schmitz C, Kiessling M, Bader B, Danek A**
Subcortical neurodegeneration in chorea: Similarities and differences between chorea-acanthocytosis and Huntington's disease.
Parkinsonism Relat Disord 2018; 49: 54-59. IF 4.360

109. **Martin DM, Moffa A, Nikolin S, Bennabi D, Brunoni AR, Flannery W, Haffen E, McClintock SM, Moreno ML, Padberg F, Palm U, Loo CK**
Cognitive effects of transcranial direct current stimulation treatment in patients with major depressive disorder: An individual patient data meta-analysis of randomised, sham-controlled trials.
Neurosci Biobehav Rev 2018; 90: 137-145. IF 8.002
110. **Menassa DA, Braeutigam S, Bailey A, Falter-Wagner CM**
Frontal evoked γ activity modulates behavioural performance in Autism Spectrum Disorders in a perceptual simultaneity task.
Neurosci Lett 2018; 665: 86-91. IF 2.173
111. **Möller HJ**
Der Zauber der Netzwerk-Metaanalysen
Neueste NM ausreichend, um den Stand zur vergleichenden Wirksamkeit/Akzeptanz der Antidepressiva darzustellen?
Psychopharmakotherapie 2018; 25: 51. IF -
112. **Möller HJ**
DSM-5: Möglichkeiten und Grenzen in der Verbesserung der Klassifikation/Diagnostik psychischer Erkrankungen.
J Neurol Neurochir Psychiatr 2018; 19: 144-153. IF -
113. **Möller HJ**
Is schizophrenia still one entity with similar symptomatic patterns, neurobiological characteristics, and treatment perspectives?
Eur Arch Psychiatry Clin Neurosci 2018; 268: 525-527. IF 3.192
114. **Möller HJ**
Possibilities and limitations of DSM-5 in improving the classification and diagnosis of mental disorders.
Psychiatr Pol. 2018; 52: 611-628. IF 1.311
115. **Möller H-J, Broich K**
Weiterbildungs-Curriculum Psychopharmakologie/Pharmakotherapie. Teil 5: Methodik klinischer psychopharmakologischer Therapieforschung (Teil II): Stichprobenselektion, Auswertungsverfahren, Metaanalysen, regulatorische Rahmenbedingungen.
Psychopharmakotherapie 2018; 25: 304-12. IF -
116. **Möller-Leimkühler AM**
Why is terrorism a man's business?
CNS Spectr 2018; 23: 119-128. IF 3.940
117. **Moritz S, Külz A, Voderholzer U, Hillebrand T, McKay D, Jelinek L**
"Phobie à deux" and other reasons why clinicians do not apply exposure with response prevention in patients with obsessive-compulsive disorder.
Cogn Behav Ther 2018: 1-15. IF 2.843
118. **Müller H, de Millas W, Gaebel W, Herrlich J, Hasan A, Janssen B, Juckel G, Karow A, Kircher T, Kiszkenow-Bäker S, Klingberg S, Klosterkötter J, Krüger-Özgürdal S, Lambert M, Lautenschlager M, Maier W, Michel TM, Mehl S, Müller BW, Pützfeld V, Rausch F, Riedel M, Sartory G, Schneider F, Wagner M, Wiedemann G, Wittorf A, Wobrock T, Wölwer W, Zink M, Bechdorf A**
Negative schemata about the self and others and paranoid ideation in at-risk states and

those with persisting positive symptoms.
Early Interv Psychiatry 2018; 12: 1157-1165. IF 3.323

119. **Müller N**
Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations.
Schizophr Bull 2018; 44: 973-982. IF 7.289
120. **Müller N**
Psychoneuroimmunologie – Zur Rolle des Immunsystems bei psychischen Störungen.
Umwelt Hygiene Arbeitsmedizin 2018; 23: 163-171. IF -
121. **Muller JL, Saimeh N, Briken P, Eucker S, Hoffmann K, Koller M, Wolf T, Dudeck M, Hartl C, Jakovljevic AK, Klein V, Knecht G, Muller-Isberner RJ, Schiltz K, Seifert D, Simon A, Steinbock H, Stuckmann W, Weissbeck W, Wiesemann C, Zeidler R**
Standards for treatment in forensic commitment according to 63 and 64 of the German criminal code.
Forensische Psychiatrie Psychologische Kriminologie 2018; 12: 93-125. IF -
122. **Müller UJ, Schiltz K, Mawrin C, Dobrowolny H, Frodl T, Bernstein HG, Bogerts B, Truebner K, Steiner J**
Total hypothalamic volume is reduced in postmortem brains of male heroin addicts.
Eur Arch Psychiatry Clin Neurosci 2018; 268: 243-248. IF 3.192
123. **Musil R, Seemüller F, Meyer S, Spellmann I, Adli M, Bauer M, Kronmüller KT, Brieger P, Laux G, Bender W, Heuser I, Fisher R, Gaebel W, Schennach R, Möller HJ, Riedel M**
Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder.
Int J Methods Psychiatr Res 2018; 27. IF 2.276
124. **Musil R, Spellmann I**
Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics.
Pharmacogenomics 2018; 19: 927-930. IF 2.265
125. **Myczkowski ML, Fernandes A, Moreno M, Valiengo L, Lafer B, Moreno RA, Padberg F, Gattaz W, Brunoni AR**
Cognitive outcomes of TMS treatment in bipolar depression: Safety data from a randomized controlled trial.
J Affect Disord 2018; 235: 20-26. IF 4.084
126. **Netter AL, Hessler JB, Diedrich A, Lehr D, Berking M, Pfeuffer S, Voderholzer U**
Usability and Naturalness of Videoconference-Based Exposure and Response Prevention for Obsessive-Compulsive Disorder at the Patients' Homes: A Pilot Study.
J Cognitive Psychotherapy 2018; 32: 303-314. IF 0.595
127. **Neumann M, Bühringer G, Höfler M, Wittchen HU, Hoch E**
Is Cannabis Use Treatment Also Indicated for Patients with Low to Moderate Polysubstance Use.
Eur Addict Res 2018; 24: 79-87. IF 1.957
128. **Neumann S, Soyka Franke AG**
Abhängigkeit von "Crystal Meth". Psychosoziale und medizinische Determinanten und aktuelle Versorgungskonzepte.

Internistische Praxis 2018; 59: 514-523. IF -

129. **Neumann S, Soyka M, Franke AG**
Bio-psycho-soziale Charakteristika und therapeutische Aspekte bei Methamphetamin-abhängigen Frauen – Gendersensible Ergebnisse einer systematischen Literaturrecherche.
Bio-Psycho-Social Characteristics and Therapeutic Aspects of Methamphetamine-Dependent Women - Gender Specific Results of a Systematic Literature Search.
Psychother Psychosom Med Psychol 2018; 68: 281-289. IF 0.835
130. **Neustädter ME, Adorjan K, Kistner N, Glaser M, Hummel I, von Saldern S, Palm U, Dehning S, Pogarell O, Karch S**
Erfolgreiche Behandlung in der Tagklinik – erlebte Veränderungen aus Sicht der Patienten.
MMW Fortschr Med 2018; 160 (Suppl5): 6-10. IF -
131. **Ni G, Gratten J, Wray NR, Lee SH; Schizophrenia Working Group of the Psychiatric Genomics Consortium**
Age at first birth in women is genetically associated with increased risk of schizophrenia.
Sci Rep 2018; 8: 10168. IF 4.011
132. **Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A, Sommer IEC, Leucht S, Kahn RS, Luykx JJ**
Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis.
Acta Psychiatr Scand 2018; 138: 281-288. IF 4.694
133. **Oviedo-Salcedo T, de Witte L, Kümpfel T, Kahn RS, Falkai P, Eichhorn P, Luykx J, Hasan A**
Absence of cerebrospinal fluid antineuronal antibodies in schizophrenia spectrum disorders.
Br J Psychiatry 2018; 212: 318-320. IF 7.233
134. **Oviedo-Salcedo T, de Witte L, Kümpfel T, Kahn RS, Falkai P, Eichhorn P, Luykx J, Hasan A**
Absence of cerebrospinal fluid antineuronal antibodies in schizophrenia spectrum disorders - CORRIGENDUM.
Br J Psychiatry 2018; 212: 318-320.
135. **Palm U, Chalah MA, Créange A, Lefaucheur JP, Ayache SS**
The evaluation of depression in multiple sclerosis using the newly proposed Multiple Sclerosis Depression Rating Scale.
Encephale 2018; 44: 565-567. IF 0.865
136. **Palm U, Kumpf U, Behler N, Wulf L, Kirsch B, Wörsching J, Keeser D, Hasan A, Padberg F**
Home Use, Remotely Supervised, and Remotely Controlled Transcranial Direct Current Stimulation: A Systematic Review of the Available Evidence.
Neuromodulation 2018; 21: 323-333 IF 2.663
137. **Papazova I, Strube W, Becker B, Henning B, Schwippel T, Fallgatter AJ, Padberg F, Palm U, Falkai P, Plewnia C, Hasan A**
Improving working memory in schizophrenia: Effects of 1 mA and 2 mA transcranial direct current stimulation to the left DLPFC.

Schizophr Res 2018; 202: 203-209. IF 4.569

138. **Papiol S, Schulze TG, Alda M**
Genetics of Lithium Response in Bipolar Disorder.
Pharmacopsychiatry 2018; 51: 206-211. IF 2.738
139. **Pernecky R**
Population-Based Approaches to Alzheimer's Disease Prevention.
Methods Mol Biol 2018; 1750: 15-29 IF -
140. **Pihlström L, Schottlaender L, Chelban V, Houlden H; MSA Exome Consortium**
LRP10 in α -synucleinopathies.
Lancet Neurol 2018; 17: 1033-1034. IF 28.755
141. **Plewnia C, Brendel B, Schwippel T, Martus P, Cordes J, Hasan A, Fallgatter AJ**
Treatment of auditory hallucinations with bilateral theta burst stimulation (cTBS):
protocol of a randomized, double-blind, placebo-controlled, multicenter trial.
Eur Arch Psychiatry Clin Neurosci. 2018; 268: 663-673 IF 3.192
142. **Preuss UW, Gouzoulis-Mayfrank E, Havemann-Reinecke U, Schäfer I, Beutel M, Hoch E, Mann KF**
Psychiatric comorbidity in alcohol use disorders: results from the German S3
guidelines.
Eur Arch Psychiatry Clin Neurosci 2018; 268: 219-229. IF 3.192
143. **Probst C, Parry CDH, Wittchen HU, Rehm J**
The socioeconomic profile of alcohol-attributable mortality in South Africa: a modelling
study.
BMC Med 2018; 16: 97. IF 8.285
144. **Proebstl L, Kamp F, Koller G, Soyka M**
Cognitive Deficits in Methamphetamine Users: How Strong is The Evidence?
Pharmacopsychiatry 2018; 51: 243-250. IF 2.738
145. **Raabe FJ, Galinski S, Papiol S, Falkai PG, Schmitt A, Rossner MJ**
Studying and modulating schizophrenia-associated dysfunctions of oligodendrocytes
with patient-specific cell systems.
NPJ Schizophr 2018; 4:23. IF -
146. **Ramos-Miguel A, Jones AA, Sawada K, Barr AM, Bayer TA, Falkai P, Leurgans SE, Schneider JA, Bennett DA, Honer WG**
Frontotemporal dysregulation of the SNARE protein interactome is associated with
faster cognitive decline in old age.
Neurobiol Dis 2018; 114: 31-44. IF 5.160
147. **Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Pernecky R; Alzheimer's Disease Neuroimaging Initiative**
CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease
continuum.
Neurobiol Aging 2018; 74: 182-190. IF 4.398
148. **Razza LB, Moffa AH, Moreno ML, Carvalho AF, Padberg F, Fregni F, Brunoni AR**
A systematic review and meta-analysis on placebo response to repetitive transcranial
magnetic stimulation for depression trials.
Prog Neuropsychopharmacol Biol Psychiatry 2018; 81: 105-113. IF 4.315

149. **Reinbold CS, Forstner AJ, Hecker J, Fullerton JM, Hoffmann P, Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, Ardaou R, Arias B, Backlund L, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Marie-Claire C, Cervantes P, Chen GB, Chen HC, Chillotti C, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dayer A, Étain B, Falkai P, Frisé L, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Jamain S, Jiménez E, Kahn JP, Kassem L, Kittel-Schneider S, Kliwicky S, König B, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, MacQueen G, Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-Érkelenz D, Rouleau GA, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm TJ, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt SH, Wright AJ, Young LT, Zandi PP, Potash JB, DePaulo JR, Bauer M, Reininghaus E, Novák T, Aubry JM, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo PH, Kato T, Grigoriu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray NR, Kelsoe JR, Alda M, McMahon FJ, Schulze TG, Rietschel M, Nöthen MM, Cichon S**
Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder.
Front Psychiatry 2018; 9: 207. IF 3.161
150. **Richieri R, Blackman G, Musil R, Spatola G, Cavanna AE, Lançon C, Régis J**
Positive clinical effects of gamma knife capsulotomy in a patient with deep brain stimulation-refractory Tourette Syndrome and Obsessive Compulsive Disorder.
Clin Neurol Neurosurg 2018; 170: 34-37. IF 1.672
151. **Rice SM, Aucote HM, Eleftheriadis D, Möller-Leimkühler AM**
Prevalence and Co-Occurrence of Internalizing and Externalizing Depression Symptoms in a Community Sample of Australian Male Truck Drivers.
Am J Mens Health 2018; 12: 74-77. IF 1.409
152. **Ricken R, Wiethoff K, Reinhold T, Stamm TJ, Baghai TC, Fisher R, Seemüller F, Brieger P, Cordes J, Laux G, Hauth I, Möller HJ, Heinz A, Bauer M, Adli M**
A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients - Results from the German Algorithm Project (GAP3).
J Affect Disord 2018; 228: 173-177. IF 4.084
153. **Ristow I, Li M, Colic L, Marr V, Födisch C, von Düring F, Schiltz K, Drumkova K, Witzel J, Walter H, Beier K, Kruger THC, Ponseti J, Schiffer B, Walter M**
Pedophilic sex offenders are characterised by reduced GABA concentration in dorsal anterior cingulate cortex.
Neuroimage Clin 2018; 18: 335-341. IF 3.943
154. **Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M**
Exzopiclone for insomnia (Review):
Cochrane Database Syst Rev 2018; 10: CD010703. IF 7.755
155. **Rohde MS, Georgescu AL, Vogeley K, Fimmers R, Falter-Wagner CM**
Absence of sex differences in mental rotation performance in autism spectrum disorder.
Autism 2018; 22: 855-865. IF 3.898
156. **Rosendahl J, Kirsten H, Hegyi E, Kovacs P, Weiss FU, Laumen H, Lichtner P, Ruffert C, Chen JM, Masson E, Beer S, Zimmer C, Seltsam K, Algül H, Bühler F, Bruno MJ, Bugert P, Burkhardt R, Cavestro GM, Cichoz-Lach H, Farré A, Frank J,**

Gambaro G, Gimpfl S, Grallert H, Griesmann H, Grützmann R, Hellerbrand C, Hegyi P, Hollenbach M, Iordache S, Jurkowska G, Keim V, Kiefer F, Krug S, Landt O, Leo MD, Lerch MM, Lévy P, Löffler M, Löhr M, Ludwig M, Macek M, Malats N, Malecka-Panas E, Malerba G, Mann K, Mayerle J, Mohr S, Te Morsche RHM, Motyka M, Mueller S, Müller T, Nöthen MM, Pedrazzoli S, Pereira SP, Peters A, Pfützer R, Real FX, Rebours V, Ridinger M, Rietschel M, Rösmann E, Saftoiu A, Schneider A, Schulz HU, Soranzo N, Soyka M, Simon P, Skipworth J, Stickel F, Strauch K, Stumvoll M, Testoni PA, Tönjes A, Werner L, Werner J, Wodarz N, Ziegler M, Masamune A, Mössner J, Férec C, Michl P, P H Drenth J, Witt H, Scholz M, Sahin-Tóth M; all members of the PanEuropean Working group on ACP
Genome-wide association study identifies inversion in the *CTRB1-CTRB2* locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis.
Gut 2018; 67: 1855-1863. IF 17.943

157. **Rozycki M, Satterthwaite TD, Koutsouleris N, Erus G, Doshi J, Wolf DH, Fan Y, Gur RE, Gur RC, Meisenzahl EM, Zhuo C, Yin H, Yan H, Yue W, Zhang D, Davatzikos CSchizophr**
Multisite Machine Learning Analysis Provides a Robust Structural Imaging Signature of Schizophrenia Detectable Across Diverse Patient Populations and Within Individuals.
Schiz Bull 2018; 44: 1035-1044. IF 7.289
158. **Rüther T, Hagedorn D, Schiela K, Schettgen T, Osiander-Fuchs H, Schober W**
Nicotine delivery efficiency of first- and second-generation e-cigarettes and its impact on relief of craving during the acute phase of use.
Int J Hyg Environ Health 2018; 221:191-198. IF 4.379
159. **Rüther T, Kiss A, Eberhardt K, Linhardt A, Kröger C, Pogarell O**
Evaluation of the cognitive behavioral smoking reduction program "Smoke_less": a randomized controlled trial.
Eur Arch Psychiatry Clin Neurosci 2018; 268: 269-277. IF 3.192
160. **Rüther T, Schultz Y, Wirth C, Chrobok A, Rabenstein A, Keeser D, Ertl-Wagner B, Pogarell O, Karch S**
Effect of smoking status on neuronal responses to graphic cigarette warning labels.
PLoS One 2018; 13: e0201360. IF 2.776
161. **Sabaß L, Padberg F, Normann C, Engel V, Konrad C, Helmle K, Jobst A, Worlitz A, Brakemeier EL**
Cognitive Behavioral Analysis System of Psychotherapy as group psychotherapy for chronically depressed inpatients: a naturalistic multicenter feasibility trial.
Eur Arch Psychiatry Clin Neurosci 2018; 268: 783-796. IF 3.192
162. **Sampaio-Junior B, Tortella G, Borrione L, Moffa AH, Machado-Vieira R, Cretaz E, Fernandes da Silva A¹, Fraguas R, Aparício LV, Klein I, Lafer B, Goerigk S, Benseñor IM, Lotufo PA, Gattaz WF, Brunoni AR**
Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial.
JAMA Psychiatry 2018; 75:158-166. IF 15.916
163. **Schaub A, Goldmann U, Mueser TK, Goerigk S, Hautzinger M, Roth E, Charypar M, Engel R, Möller HJ**
Efficacy of extended clinical management, group CBT, and group plus individual CBT for major depression: Results of a two-year follow-up study.
J Affect Disord 2018; 238: 570-578. IF 4.084

164. **Schiltz K**
Gewalt in der geschlossenen Unterbringung.
In: Ducker M, Steger F (Hrsg). Ethik in der Forensischen Psychiatrie und Psychotherapie. MWV, Berlin, S. 189-197.
165. **Schlegl S, Dittmer N, Hoffmann S, Voderholzer U**
Self-reported quantity, compulsiveness and motives of exercise in patients with eating disorders and healthy controls: differences and similarities.
J Eat Disord 2018; 6: 17. IF -
166. **Schmitt A., Malchow B., Lembeck M., Maurus I., Roeh A., Papiol S., Hasan A., Falkai P**
Bedeutung von Ausdauersport für die Verbesserung von Kognition und Remission bei post-akuter Schizophrenia.
Nervenheilkunde 2018; 37: 324-29. IF -
167. **Schmitt A, Maurus I, Rossner MJ, Röh A, Lembeck M, von Wilmsdorff M, Takahashi S, Rauchmann B, Keeser D, Hasan A, Malchow B, Falkai P**
Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased Mortality.
Front Psychiatry 2018; 9: 690. IF 3.161
168. **Schnell JML, Weidinger E, Musil R**
Patienten mit Tics.
MMW Fortschr Med 2018; 160: 47-50. IF -
169. **Schneider M, Greiner T, Heinze M, Degner D, Grohmann R, Toto S**
Blutungsneigung unter Escitaloprom.
Psychopharmakotherapie 2018; 25: 36-9. IF -
170. **Schubert C, Voderholzer U, Wolstein J, Külz AK, Schwartz C**
Wirkfaktoren der kognitiven Verhaltenstherapie von Zwangsstörungen: Ein kritischer Überblick über den aktuellen Forschungsstand.
Verhaltenstherapie 2018; 28: 35-43. IF 1.073
171. **Schwartz C, Hilbert S, Schlegl S, Diedrich A, Voderholzer U**
Common change factors and mediation of the alliance-outcome link during treatment of depression.
J Consult Clin Psychol 2018; 86: 584-592. IF 4.358
172. **Schwippel T, Papazova I, Strube W, Fallgatter AJ, Hasan A, Plewnia C**
Beneficial effects of anodal transcranial direct current stimulation (tDCS) on spatial working memory in patients with schizophrenia.
Eur Neuropsychopharmacol. 2018; 28: 1339-1350. IF 4.468
173. **Shang J, Bäuml JG, Koutsouleris N, Daamen M, Baumann N, Zimmer C, Bartmann P, Boecker H, Wolke D, Sorg C**
Decreased BOLD fluctuations in lateral temporal cortices of premature born adults.
Hum Brain Mapp 2018; 39: 4903-4912. IF 4.554
174. **Soboka M, Adorjan K, Dehning S, Asaminew T, Abera M, Siebeck M, Tesfaye M, Jobst A**
Evaluation of a Master of Science in Integrated Clinical and Community Mental Health (MSc ICCMH) program in Ethiopia.
Ger Med Sci 2018; 16: eCollection. IF -

175. **Soyka M**
Alkoholkonsumstörung. Diagnostik und Therapie der Alkoholabhängigkeit.
DNP Der Neurologe & Psychiater 2018; 19: 64-68. IF -
176. **Soyka M**
Suchterkrankungen.
In: Sautermeister J, Skuban T (Hrsg). Handbuch psychiatrisches Grundwissen für die Seelsorge.
Herder, 2018, S. 444-463.
177. **Soyka M**
Therapie der Benzodiazepinabhängigkeit.
PSYCH up2date 2018; 12: 363-374. IF -
178. **Spellmann I, Reinhard MA, Veverka D, Zill P, Obermeier M, Dehning S, Schennach R, Müller N, Möller HJ, Riedel M, Musil R**
QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors.
Eur Arch Psychiatry Clin Neurosci 2018; 268: 383-390. IF 3.192
179. **Stefanescu MR, Endres RJ, Hilbert K, Wittchen HU, Lueken U**
Networks of phobic fear: Functional connectivity shifts in two subtypes of specific phobia.
Neurosci Lett 2018; 662: 167-172. IF 2.173
180. **Steffens M, Meyhöfer I, Fassbender K, Ettinger U, Kambeitz J**
Association of Schizotypy With Dimensions of Cognitive Control: A Meta-Analysis.
Schizophr Bull 2018; 44(Suppl2): S512-S524. IF 7.289
181. **Steiner J, Prüb H, Köhler S, Hasan A, Falkai P**
Autoimmunenenzephalitis mit psychotischer Symptomatik. Diagnostik, Warnhinweise und praktisches Vorgehen.
Nervenarzt 2018; 89: 530-538. IF 0.829
182. **Strobel C, Quadflieg N, Voderholzer U, Naab S, Fichter MM**
Short- and long-term outcome of males treated for anorexia nervosa: a review of the literature.
Eat Weight Disord 2018; 23: 541-552 IF 2.730
183. **Stubbs B, Vancampfort D, Hallgren M, Firth J, Veronese N, Solmi M, Brand S, Cordes J, Malchow B, Gerber M, Schmitt A, Correll CU, De Hert M, Gaughran F, Schneider F, Kinnafick F, Falkai P, Möller HJ, Kahl KG**
EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH).
Eur Psychiatry 2018; 54: 124-144. IF 3.941
184. **Stübner S, Grohmann R, Eckermann G, Hiemke C, Lorenzl S**
Psychopharmaka in der Palliativmedizin. Diskussionswürdige Praxis.
Deutsch Ärzteblatt 2018; 115: A868-A871. IF -
185. **Stübner S, Grohmann R, Greil W, Zhang X, Müller-Oerlinghausen B, Bleich S, Rütther E, Möller HJ, Engel R, Falkai P, Toto S, Kasper S, Neyazi A**
Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance

Project.

Int J Neuropsychopharmacol 2018; 21: 814-821. IF 4.207

186. **Tolic I, Soyka M**
[Stress Response in Persons with Alcohol Addiction in the Context of Abstinence Duration and Disease Severity].
Fortschr Neurol Psychiatr 2018; 86: 3556-367. IF 0.635
187. **Vignaud P, Mondino M, Poulet E, Palm U, Brunelin J**
Duration but not intensity influences transcranial direct current stimulation (tDCS) after-effects on cortical excitability.
Neurophysiol Clin 2018; 48: 89-92 IF 2.167
188. **Voderholzer U, Barton B**
Psychotherapieverfahren und Methoden.
In: Voderholzer U, Hohagen F (Hrsg). Therapie psychischer Erkrankungen. Elsevier, Elsevier, München, 2018, S. 519-527.
189. **Voderholzer U, Barton B, Rosner R**
Bedeutung sexuellen Missbrauchs für psychische Erkrankungen.
In: Voderholzer U, Hohagen F (Hrsg). Therapie psychischer Erkrankungen. Elsevier, Elsevier, München, 2018, S. 557-564.
190. **Volkert J, Andreas S, Härter M, Dehoust MC, Sehner S, Suling A, Ausín B, Canuto A, Crawford MJ, Da Ronch C, Grassi L, Hershkovitz Y, Muñoz M, Quirk A, Rotenstein O, Santos-Olmo AB, Shalev AY, Strehle J, Weber K, Wegscheider K, Wittchen HU, Schulz H**
Predisposing, enabling, and need factors of service utilization in the elderly with mental health problems.
Int Psychogeriatr 2018; 30: 1027-1037. IF 2.478
191. **Von Hirsch A, Hippus H, Müller N**
Emil Kraepelin und die Krankheit von James Loeb.
In: Salmen, G, Meyer H (Hrsg). James Loeb, Sammler und Mäzen in München, Murnau und weltweit. Hirmer, 2018, S. 151-163.
192. **von Wilmsdorff M, Manthey F, Bouvier ML, Staehlin O, Falkai P, Meisenzahl-Lechner E, Schmitt A, Gebicke-Haerter PJ**
Effects of haloperidol and clozapine on synapse-related gene expression in specific brain regions of male rats.
Eur Arch Psychiatry Clin Neurosci 2018; 268: 555-563. IF 3.192
193. **Wagner E, Hasan A**
Cariprazin – eine neue medikamentöse Therapieoption in der Schizophreniebehandlung.
Psychopharmakotherapie 2018; 25: 278-85. IF -
194. **Wagner E, Raabe F, Martin G, Winter C, Plörer D, Krause DL, Adorjan K, Koller G, Pogarell O**
Concomitant drug abuse of opioid dependent patients in maintenance treatment detected with a multi-target screening of oral fluid.
Am J Addict 2018; 27: 407-412. IF 1.946
195. **Walters RK, Polimanti R, Johnson EC, McClintick JN, Adams MJ, Adkins AE, Aliev F, Bacanu SA, Batzler A, Bertelsen S, Biernacka JM, Bigdeli TB, Chen LS, Clarke TK, Chou YL, Degenhardt F, Docherty AR, Edwards AC, Fontanillas P, Foo JC, Fox**

L, Frank J, Giegling I, Gordon S, Hack LM, Hartmann AM, Hartz SM, Heilmann-Heimbach S, Herms S, Hodgkinson C, Hoffmann P, Jan Hottenga J, Kennedy MA, Alanne-Kinnunen M, Konte B, Lahti J, Lahti-Pulkkinen M, Lai D, Ligthart L, Loukola A, Maher BS, Mbarek H, McIntosh AM, McQueen MB, Meyers JL, Milaneschi Y, Palviainen T, Pearson JF, Peterson RE, Ripatti S, Ryu E, Saccone NL, Salvatore JE, Sanchez-Roige S, Schwandt M, Sherva R, Streit F, Strohmaier J, Thomas N, Wang JC, Webb BT, Wedow R, Wetherill L, Wills AG; 23andMe Research Team, Boardman JD, Chen D, Choi DS, Copeland WE, Culverhouse RC, Dahmen N, Degenhardt L, Domingue BW, Elson SL, Frye MA, Gäbel W, Hayward C, Ising M, Keyes M, Kiefer F, Kramer J, Kuperman S, Lucae S, Lynskey MT, Maier W, Mann K, Männistö S, Müller-Myhsok B, Murray AD, Nurnberger JI, Palotie A, Preuss U, Räikkönen K, Reynolds MD, Ridinger M, Scherbaum N, Schuckit MA, Soyka M, Treutlein J, Witt S, Wodarz N, Zill P, Adkins DE, Boden JM, Boomsma DI, Bierut LJ, Brown SA, Bucholz KK, Cichon S, Costello EJ, de Wit H, Diazgranados N, Dick DM, Eriksson JG, Farrer LA, Foroud TM, Gillespie NA, Goate AM, Goldman D, Gruzca RA, Hancock DB, Harris KM, Heath AC, Hesselbrock V, Hewitt JK, Hopfer CJ, Horwood J, Iacono W, Johnson EO, Kaprio JA, Karpyak VM, Kendler KS, Kranzler HR, Krauter K, Lichtenstein P, Lind PA, McGue M, MacKillop J, Madden PAF, Maes HH, Magnusson P, Martin NG, Medland SE, Montgomery GW, Nelson EC, Nöthen MM, Palmer AA, Pedersen NL, Penninx BWJH, Porjesz B, Rice JP, Rietschel M, Riley BP, Rose R, Rujescu D, Shen PH, Silberg J, Stallings MC, Tarter RE, Vanyukov MM, Vrieze S, Wall TL, Whitfield JB, Zhao H, Neale BM, Gelernter J, Edenberg HJ, Agrawal A

Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders.

Nat Neurosci. 2018; 21:1656-1669. IF 21.126

196. **Weber A, Schwarz SC, Tost J, Trümbach D, Winter P, Busato F, Tacik P, Windhorst AC, Fagny M, Arzberger T, McLean C, van Swieten JC, Schwarz J, Vogt Weisenhorn D, Wurst W, Adhikary T, Dickson DW, Höglinger GU, Müller U**
Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1.
Nat Commun 2018; 9: 2929. IF 11.878
197. **Weinmann T, Vetter C, Karch S, Nowak D, Radon K**
Shift work and cognitive impairment in later life - results of a cross-sectional pilot study testing the feasibility of a large-scale epidemiologic investigation.
BMC Public Health. 2018; 18: 1256. IF 2.567
198. **Winter J, Falkai P, Schüle C**
Der weinende Patient.
MMW Fortschr Med 2018; 160: 50-53. IF -
199. **Wittchen HU, Beesdo-Baum K**
"Throwing out the baby with the bathwater"? Conceptual and methodological limitations of the HiTOP approach.
World Psychiatry 2018; 17: 298-299. IF 34.024
200. **Wörsching J, Padberg F, Goerigk S, Heinz I, Bauer C, Plewnia C, Hasan A, Ertl-Wagner B, Keeser D**
Testing assumptions on prefrontal transcranial direct current stimulation: Comparison of electrode montages using multimodal fMRI.
Brain Stimul 2018; 11: 998-1007. IF 6.919
201. **Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, Adams MJ, Agerbo E, Air TM, Andlauer TMF, Bacanu SA, Bækvad-Hansen M, Beekman**

AFT, Bigdeli TB, Binder EB, Blackwood DRH, Bryois J, Buttenschøn HN, Bybjerg-Grauholm J, Cai N, Castelao E, Christensen JH, Clarke TK, Coleman JIR, Colodro-Conde L, Couvy-Duchesne B, Craddock N, Crawford GE, Crowley CA, Dashti HS, Davies G, Deary IJ, Degenhardt F, Derks EM, Direk N, Dolan CV, Dunn EC, Eley TC, Eriksson N, Escott-Price V, Kiadeh FHF, Finucane HK, Forstner AJ, Frank J, Gaspar HA, Gill M, Giusti-Rodríguez P, Goes FS, Gordon SD, Grove J, Hall LS, Hannon E, Hansen CS, Hansen TF, Herms S, Hickie IB, Hoffmann P, Homuth G, Horn C, Hottenga JJ, Hougaard DM, Hu M, Hyde CL, Ising M, Jansen R, Jin F, Jorgenson E, Knowles JA, Kohane IS, Kraft J, Kretzschmar WW, Krogh J, Kutalik Z, Lane JM, Li Y, Li Y, Lind PA, Liu X, Lu L, MacIntyre DJ, MacKinnon DF, Maier RM, Maier W, Marchini J, Mbarek H, McGrath P, McGuffin P, Medland SE, Mehta D, Middeldorp CM, Mihailov E, Milaneschi Y, Milani L, Mill J, Mondimore FM, Montgomery GW, Mostafavi S, Mullins N, Nauck M, Ng B, Nivard MG, Nyholt DR, O'Reilly PF, Oskarsson H, Owen MJ, Painter JN, Pedersen CB, Pedersen MG, Peterson RE, Pettersson E, Peyrot WJ, Pistis G, Posthuma D, Purcell SM, Quiroz JA, Qvist P, Rice JP, Riley BP, Rivera M, Saeed Mirza S, Saxena R, Schoevers R, Schulte EC, Shen L, Shi J, Shyn SI, Sigurdsson E, Sinnamoni GBC, Smit JH, Smith DJ, Stefansson H, Steinberg S, Stockmeier CA, Streit F, Strohmaier J, Tansey KE, Teismann H, Teumer A, Thompson W, Thomson PA, Thorgeirsson TE, Tian C, Traylor M, Treutlein J, Trubetskoy V, Uitterlinden AG, Umbricht D, Van der Auwera S, van Hemert AM, Viktorin A, Visscher PM, Wang Y, Webb BT, Weinsheimer SM, Wellmann J, Willemsen G, Witt SH, Wu Y, Xi HS, Yang J, Zhang F; eQTLGen; 23andMe, Arolt V, Baune BT, Berger K, Boomsma DI, Cichon S, Dannlowski U, de Geus ECJ, DePaulo JR, Domenici E, Domschke K, Esko T, Grabe HJ, Hamilton SP, Hayward C, Heath AC, Hinds DA, Kendler KS, Kloiber S, Lewis G, Li QS, Lucae S, Madden PFA, Magnusson PK, Martin NG, McIntosh AM, Metspalu A, Mors O, Mortensen PB, Müller-Myhsok B, Nordentoft M, Nöthen MM, O'Donovan MC, Paciga SA, Pedersen NL, Penninx BWJH, Perlis RH, Porteous DJ, Potash JB, Preisig M, Rietschel M, Schaefer C, Schulze TG, Smoller JW, Stefansson K, Tiemeier H, Uher R, Völzke H, Weissman MM, Werge T, Winslow AR, Lewis CM, Levinson DF, Breen G, Børglum AD, Sullivan PF; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression.

Nat Genet 2018; 50: 668-681 IF 25.455

202. **Yasmeen S, Burger P, Friedrichs S, Papiol S, Bickeböller H**
Relating drug response to epigenetic and genetic markers using a region-based kernel score test.
BMC Proc. 2018; 12 (Suppl 9): 47. IF -
203. **Yitayih Y, Abera M, Tesfaye E, Mamaru A, Soboka M, Adorjan K**
Substance use disorder and associated factors among prisoners in a correctional institution in Jimma, Southwest Ethiopia: a cross-sectional study.
BMC Psychiatry 2018; 18: 314. IF 2.666
204. **Zellner A, Scharrer E, Arzberger T, Oka C, Domenga-Denier V, Joutel A, Lichtenthaler SF, Müller SA, Dichgans M, Haffner C**
CADASIL brain vessels show a HTRA1 loss-of-function profile.
Acta Neuropathol 2018; 136: 111-125. IF 18.174
205. **Zhang M, Ferrari R, Tartaglia MC, Keith J, Surace EI, Wolf U, Sato C, Grinberg M, Liang Y, Xi Z, Dupont K, McGoldrick P, Weichert A, McKeever PM, Schneider R, McCorkindale MD, Manzoni C, Rademakers R, Graff-Radford NR, Dickson DW, Parisi JE, Boeve BF, Petersen RC, Miller BL, Seeley WW, van Swieten JC, van Rooij J, Pijnenburg Y, van der Zee J, Van Broeckhoven C, Le Ber I, Van Deerlin V, Suh E,**

Rohrer JD, Mead S, Graff C, Öijerstedt L, Pickering-Brown S, Rollinson S, Rossi G, Tagliavini F, Brooks WS, Dobson-Stone C, Halliday GM, Hodges JR, Piguet O, Binetti G, Benussi L, Ghidoni R, Nacmias B, Sorbi S, Bruni AC, Galimberti D, Scarpini E, Rainero I, Rubino E, Clarimon J, Lleó A, Ruiz A, Hernández I, Pastor P, Diez-Fairen M, Borroni B, Pasquier F, Deramecourt V, Lebouvier T, Perneczky R, Diehl-Schmid J, Grafman J, Huey ED, Mayeux R, Nalls MA, Hernandez D, Singleton A, Momeni P, Zeng Z, Hardy J, Robertson J, Zinman L, Rogaeva E; International FTD-Genomics Consortium (IFGC)

A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers.
Brain 2018; 141: 2895-2907. IF 11.814